Что такое event «AI for Science» от Anthropic?
The Briefing: AI for Science — live stream из San Francisco 30 июня 2026 в 10:00 PST. Agenda: vision Anthropic для AI в scientific research, Claude for Life Sciences demos и customer spotlights от top pharmaceutical и biotech companies.
| Speaker | Role |
|---|---|
| Vas Narasimhan | CEO Novartis; board member Anthropic |
| Chris Boerner, PhD | CEO Bristol Myers Squibb |
| Aviv Regev | EVP & Head of R&D, Genentech |
| Lotte Bjerre Knudsen | Professor, DMSc; ex Chief Scientific Adviser Novo Nordisk |
| Eric Kauderer-Abrams | Head of Life Sciences, Anthropic |
| Jonah Cool | Head of Life Sciences Partnerships, Anthropic |
| Matthew Herper | Senior Writer, STAT News (moderator) |
Когда CEO Novartis и BMS выходят на сцену AI-компании — это не marketing stunt, а signal о direction pharmaceutical R&D. Traditional drug development: 12–15 лет, cost >$2.6B; только ~10% clinical candidates доходят до approval.
Target ID lag: Mining миллионов papers раньше занимал months; AI сжимает до hours.
Compound design bottleneck: Wet-lab screening медленный и failure-prone; simulation ускоряет на orders of magnitude.
Regulatory documentation drag: CSR пишутся months — core pain point Novo Nordisk.
Compliance & explainability: Pharma требует auditable AI outputs; Constitutional AI path Anthropic fit лучше.
Cross-border access risk: Mythos 5 export controls создают real uncertainty для international pharma teams.
Кто такой John Jumper и почему его move в Anthropic — big deal
John Michael Jumper (b. 1985, Little Rock, Arkansas): Vanderbilt BS math/physics → Cambridge MPhil physics (Marshall Scholar) → University of Chicago PhD theoretical chemistry (2017). Через шесть месяцев после PhD — Google DeepMind, secret protein-folding project AlphaFold.
CASP14 2020: AlphaFold 2 достиг experimental-grade accuracy за hours, не months. Impact: 214M+ predicted structures; 2M+ researchers в 190+ countries. 2024 — Nobel Prize in Chemistry Jumper и Demis Hassabis (с David Baker, UW). В 39 лет — youngest chemistry laureate за 70+ лет.
19 июня 2026 Jumper posted: «After nearly nine years, I have decided to leave Google DeepMind and join Anthropic.» Hassabis ответил публично. Announcement за 11 дней до сегодняшнего briefing — choreographed или coincidence, но frames весь science narrative Anthropic. Role undisclosed; likely steering foundational biological AI, возможно «ClaudeFold»-class tool.
| Date | Event |
|---|---|
| Oct 2025 | Claude for Life Sciences launch |
| Feb 2026 | Allen Institute & HHMI Janelia partnerships |
| Apr 2026 | Coefficient Bio acquired (~$400M) |
| May 2026 | Andrej Karpathy joins pre-training team |
| Jun 9, 2026 | Claude Fable 5 + Mythos 5 launch |
| Jun 12, 2026 | US orders Fable 5 & Mythos 5 offline |
| Jun 19, 2026 | Jumper → Anthropic announced |
| Jun 24, 2026 | Bloomberg: AlphaFold co-authors Adler & Pritzel may follow (unconfirmed) |
| Jun 26, 2026 | Mythos 5 partially restored for ~100 US orgs |
| Jun 30, 2026 | AI for Science briefing |
Claude for Life Sciences: stack и реальные capabilities
Launch October 2025 — Claude Enterprise с MCP connectors в tools, которые scientists уже используют daily.
| Platform | Capability |
|---|---|
| Benchling | Draft protocols, SOPs, informed consent из ELN/LIMS |
| 10x Genomics | Single-cell & spatial transcriptomics |
| PubMed | Search, retrieve, synthesize papers с citations |
| bioRxiv / medRxiv | Preprint access до formal publication |
| Open Targets | Target identification & prioritization |
| Medidata | Trial enrollment & site performance monitoring |
| ClinicalTrials.gov | Competitive landscape из registries |
| Wiley Scholar Gateway | Full-text journal access |
| BioRender | Scientific figure workflows |
Coverage: early discovery (literature, hypotheses, target ID) → preclinical (genomics, scRNA-seq QC, tox prediction) → clinical (FDA/NIH-aware protocols, enrollment monitoring) → regulatory (gap analysis, agency query responses).
Coefficient Bio (Apr 2026, ~$400M all-stock): Founders Samuel Stanton & Nathan C. Frey из Genentech Prescient Design. Goal: «ASI for Science.» Investor Dimension reported 38,513% IRR. Team merged в Anthropic healthcare под Eric Kauderer-Abrams — protein design и biomolecule modeling, bridge от assistants к настоящим drug-discovery engines.
Шестишаговый runbook после AI for Science briefing
Track live announcements: Jumper role reveal, Mythos 5 biology access expansion, Fable 5 restoration, new partners. Official: Claude for Life Sciences, Fable 5 & Mythos 5 report.
Map Mythos 5 access: As of June 30 — только ~100 vetted US orgs. International teams нужны compliance fallbacks — см. Fable 5 ban & alternatives guide.
Prioritize MCP connectors: Align Benchling, PubMed, Medidata integrations к вашему pipeline stage. Study NovoScribe RAG + expert-approved templates.
Dual-track model routing: Claude для heavy science tasks; OpenAI/Google/domestic alternatives для policy shocks. См. AI coding assistant comparison.
Watch international paths: Non-US researchers locked out из most capable science models Anthropic — plan regional AI stacks accordingly.
Lock stable Apple Silicon hosts: Bioinformatics pipelines и Claude Code agents требуют 7×24 uptime. Evaluate MESHLAUNCH cloud Mac rental — laptops sleep; Linux VPS lacks Metal и Xcode.
Насколько хорош Claude Mythos 5 в real science?
| Benchmark | Result |
|---|---|
| Drug design speed | ~×10 на key steps, zero human help |
| Hit rate | 9 / 14 protein targets → strong candidates |
| Workflow | Binding sites → tool selection → design runs → self-recovery from failures |
| Target classes | Immune checkpoints, growth-factor signaling, neurodegeneration, muscle disease, structural targets |
| AAV capsid (Dyno data) | Beat dedicated protein language models |
| Hypothesis blind test | ~80% human preference vs prior Opus; E. coli antimicrobial target validated in lab |
| Autonomous genomics (1 week) | 138 species, millions of cells; custom ML model 100× smaller than recent Science model, better performance |
Novo Nordisk (Ozempic maker): CSRs bottlenecked approvals. Built NovoScribe on Claude via Amazon Bedrock + RAG с domain-expert templates.
«Claude has helped us cut writing times on CSRs by 90% so we can get documentation directly into human hands for review and approval.» — Waheed Jowiya, Digitalization Strategy Director
Expanding to device protocols, patient materials, full CTD automation. Case study: claude.com/customers/novo-nordisk.
Other deployments: Sanofi, AbbVie, AstraZeneca, Genmab, Bristol Myers Squibb; plus Komodo Health (analytics) и Axiom (Claude Code + MCP tox prediction).
| Dimension | Anthropic edge | Peers |
|---|---|---|
| Safety culture | Constitutional AI, regulatory-friendly | Mixed approaches |
| Vertical stack | Connectors + Coefficient Bio + Jumper | DeepMind has AlphaFold, different GTM |
| Enterprise lock-in | Novartis, BMS, Genentech, Novo Nordisk depth | Expanding competition |
Export control cloud: Since June 12 — Fable 5 и Mythos 5 pulled для foreign-national access. June 26: Mythos 5 partially restored для ~100 US critical-infrastructure orgs. Fable 5 still down; negotiations ongoing. International pharma employees at showcased companies face operational uncertainty.
Can Jumper replicate AlphaFold at Anthropic? Genuinely unknown. AlphaFold имел DeepMind infrastructure, deep biology partnerships, crisp CASP benchmark. Anthropic — commercial LLM company pivoting в scientific AI; knowledge Jumper invaluable, но product breakthroughs need org-wide execution.
×10 design acceleration: Internal Mythos 5 benchmark, 9/14 autonomous hits.
90% CSR reduction: NovoScribe measured outcome, not marketing copy.
214M structures legacy: AlphaFold scale Jumper brings в product arc Anthropic.
Note: Written around June 30 livestream. Post-event updates recommended: product announcements, Jumper official role, Fable 5 restoration, new pharma deals. Sources: Anthropic, STAT News, Nobel Foundation, Novo Nordisk case study.
Life-science AI pipelines need stable compute — sleeping laptops, shared instances, Metal-less Linux VPS eat efficiency, которую обещает Mythos 5. Для 7×24 bioinformatics agents, parallel analysis, macOS toolchain work — MESHLAUNCH cloud Mac Mini rental обычно лучший production choice. См. Anthropic IPO guide для capital context (центр помощи).
Live briefing 30 июня 2026 (10:00 PST) с Claude demos и pharma case studies. Cloud Mac pricing на странице тарифов.
AlphaFold 2 lead, Nobel Chemistry 2024 (youngest за 70+ years). DeepMind → Anthropic 19 июня 2026. Lecture: nobelprize.org.
~×10 на key steps в internal testing; 9/14 protein targets yielded strong candidates с full autonomous workflow без human assistance.
Только ~100 vetted US organizations на 30 июня. Fable 5 suspended с 12 июня. См. alternatives guide и центр помощи.
Anthropic, April 2026, ~$400M. <10 employees, mostly ex-Genentech computational biology, building AI drug discovery — brought protein design expertise in-house.